Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 5.11
BDSI's Cash to Debt is ranked higher than
67% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. BDSI: 5.11 )
BDSI' s 10-Year Cash to Debt Range
Min: 0.05   Max: No Debt
Current: 5.11

Equity to Asset 0.63
BDSI's Equity to Asset is ranked higher than
68% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. BDSI: 0.63 )
BDSI' s 10-Year Equity to Asset Range
Min: -2.52   Max: 0.87
Current: 0.63

-2.52
0.87
F-Score: 2
Z-Score: 7.05
M-Score: 9.54
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -496.67
BDSI's Operating margin (%) is ranked higher than
59% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. BDSI: -496.67 )
BDSI' s 10-Year Operating margin (%) Range
Min: -10722.77   Max: 63.88
Current: -496.67

-10722.77
63.88
Net-margin (%) -505.41
BDSI's Net-margin (%) is ranked higher than
58% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. BDSI: -505.41 )
BDSI' s 10-Year Net-margin (%) Range
Min: -12468.81   Max: 6552.47
Current: -505.41

-12468.81
6552.47
ROA (%) -151.02
BDSI's ROA (%) is ranked higher than
50% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. BDSI: -151.02 )
BDSI' s 10-Year ROA (%) Range
Min: -333.21   Max: 129.21
Current: -151.02

-333.21
129.21
ROC (Joel Greenblatt) (%) -1865.76
BDSI's ROC (Joel Greenblatt) (%) is ranked higher than
60% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -247.50 vs. BDSI: -1865.76 )
BDSI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -14144.88   Max: 1072.11
Current: -1865.76

-14144.88
1072.11
Revenue Growth (%) 26.00
BDSI's Revenue Growth (%) is ranked higher than
91% of the 624 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. BDSI: 26.00 )
BDSI' s 10-Year Revenue Growth (%) Range
Min: -65.8   Max: 426.6
Current: 26

-65.8
426.6
EBITDA Growth (%) 30.70
BDSI's EBITDA Growth (%) is ranked higher than
96% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. BDSI: 30.70 )
BDSI' s 10-Year EBITDA Growth (%) Range
Min: -47.3   Max: 52.9
Current: 30.7

-47.3
52.9
EPS Growth (%) 39.20
BDSI's EPS Growth (%) is ranked higher than
97% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. BDSI: 39.20 )
BDSI' s 10-Year EPS Growth (%) Range
Min: -68.1   Max: 68.4
Current: 39.2

-68.1
68.4
» BDSI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

BDSI Guru Trades in Q1 2013

Steven Cohen 22,127 sh (+28.46%)
Jim Simons 158,400 sh (+7.32%)
» More
Q2 2013

BDSI Guru Trades in Q2 2013

Steven Cohen Sold Out
Jim Simons Sold Out
» More
Q4 2013

BDSI Guru Trades in Q4 2013

Julian Robertson 510,874 sh (New)
» More
Q1 2014

BDSI Guru Trades in Q1 2014

Julian Robertson 510,874 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with BDSI

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Julian Robertson 2013-12-31 New Buy0.92%$4.24 - $5.98 $ 12.81150%510874
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 9.56
BDSI's P/B is ranked higher than
62% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 5.80 vs. BDSI: 9.56 )
BDSI' s 10-Year P/B Range
Min: 2.36   Max: 337
Current: 9.56

2.36
337
P/S 17.79
BDSI's P/S is ranked higher than
72% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 18.96 vs. BDSI: 17.79 )
BDSI' s 10-Year P/S Range
Min: 0.89   Max: 603
Current: 17.79

0.89
603
EV-to-EBIT -13.09
BDSI's EV-to-EBIT is ranked higher than
68% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. BDSI: -13.09 )
BDSI' s 10-Year EV-to-EBIT Range
Min: 0.7   Max: 32.5
Current: -13.09

0.7
32.5
Current Ratio 3.58
BDSI's Current Ratio is ranked higher than
71% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. BDSI: 3.58 )
BDSI' s 10-Year Current Ratio Range
Min: 0.03   Max: 6.96
Current: 3.58

0.03
6.96
Quick Ratio 3.58
BDSI's Quick Ratio is ranked higher than
73% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. BDSI: 3.58 )
BDSI' s 10-Year Quick Ratio Range
Min: 0.03   Max: 6.96
Current: 3.58

0.03
6.96

Valuation & Return

vs
industry
vs
history
Price/Net Cash 12.43
BDSI's Price/Net Cash is ranked higher than
80% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 63.00 vs. BDSI: 12.43 )
BDSI' s 10-Year Price/Net Cash Range
Min: 2.08   Max: 176.5
Current: 12.43

2.08
176.5
Price/Net Current Asset Value 11.98
BDSI's Price/Net Current Asset Value is ranked higher than
79% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 43.44 vs. BDSI: 11.98 )
BDSI' s 10-Year Price/Net Current Asset Value Range
Min: 2.08   Max: 88.25
Current: 11.98

2.08
88.25
Price/Tangible Book 10.85
BDSI's Price/Tangible Book is ranked higher than
67% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 8.86 vs. BDSI: 10.85 )
BDSI' s 10-Year Price/Tangible Book Range
Min: 1.9   Max: 75
Current: 10.85

1.9
75
Price/Median PS Value 1.11
BDSI's Price/Median PS Value is ranked higher than
80% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. BDSI: 1.11 )
BDSI' s 10-Year Price/Median PS Value Range
Min: 0.06   Max: 35.63
Current: 1.11

0.06
35.63
Earnings Yield (Greenblatt) 1.80
BDSI's Earnings Yield (Greenblatt) is ranked higher than
70% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 4.70 vs. BDSI: 1.80 )
BDSI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.1   Max: 148
Current: 1.8

3.1
148
Forward Rate of Return (Yacktman) -1.51
BDSI's Forward Rate of Return (Yacktman) is ranked higher than
85% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -10.93 vs. BDSI: -1.51 )
BDSI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -14.2   Max: 0.6
Current: -1.51

-14.2
0.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:BD5.Germany
BioDelivery Sciences International, Inc., was incorporated in the State of Indiana on January 6, 1997 and reincorporated as a Delaware corporation in 2002. The Company is a specialty pharmaceutical company that is utilizing licensed and owned proprietary drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new formulations of proven therapeutics. Utilizing its drug delivery technologies, it is developing formulations of pharmaceuticals aimed mainly at acute conditions occurring in patients, mostly notably in the areas of pain and fungal infections. In formulating its products and product candidates, it utilizes the novel, patent protected and proprietary BioErodible MucoAdhesive ("BEMA") drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). Its first U.S. Food and Drug Administration approved product, ONSOLIS, as well as its pipeline of product candidates; utilize its BEMA technology. On July 16, 2009, the Company announced the U.S. approval of its first product, ONSOLIS. It is indicated for the treatment of breakthrough pain (i.e., pain that "breaks through" the effects of other medications being used to control persistent pain) in opioid tolerant patients with cancer. Its next product, currently in development, is BEMA Buprenorphine, a potential treatment for moderate to severe chronic pain. Its BioErodible MucoAdhesive (known as BEMA) drug delivery technology consists of a small, bi-layered erodible polymer film for application to the buccal mucosa (the lining inside the cheek). BEMA films have the capability to deliver a rapid, reliable dose of drug across the buccal mucosa for time-critical conditions such as "breakthrough" cancer pain or in situations where gastrointestinal absorption of an oral drug is not practical or reliable, such as nausea and vomiting. The Company is subject to regulation for safety, efficacy and quality by governmental authorities in the United States and other countries.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide